MYC levels regulate metastatic heterogeneity in pancreatic adenocarcinoma Journal Article


Authors: Maddipati, R.; Norgard, R. J.; Baslan, T.; Rathi, K. S.; Zhang, A.; Saeid, A.; Higashihara, T.; Wu, F.; Kumar, A.; Annamalai, V.; Bhattacharya, S.; Raman, P.; Adkisson, C. A.; Pitarresi, J. R.; Wengyn, M. D.; Yamazoe, T.; Li, J.; Balli, D.; LaRiviere, M. J.; Ngo, T. V. C.; Folkert, I. W.; Millstein, I. D.; Bermeo, J.; Carpenter, E. L.; McAuliffe, J. C.; Oktay, M. H.; Brekken, R. A.; Lowe, S. W.; Iacobuzio-Donahue, C. A.; Notta, F.; Stanger, B. Z.
Article Title: MYC levels regulate metastatic heterogeneity in pancreatic adenocarcinoma
Abstract: The degree of metastatic disease varies widely among patients with cancer and affects clinical outcomes. However, the biological and functional differences that drive the extent of metastasis are poorly understood. We analyzed primary tumors and paired metastases using a multifluorescent lineage-labeled mouse model of pancreatic ductal adenocarcinoma (PDAC)—a tumor type in which most patients present with metastases. Genomic and transcriptomic analysis revealed an association between metastatic burden and gene amplification or transcriptional upregulation of MYC and its downstream targets. Functional experiments showed that MYC promotes metastasis by recruiting tumor-associated macrophages, leading to greater bloodstream intravasation. Consistent with these findings, metastatic progression in human PDAC was associated with activation of MYC signaling pathways and enrichment for MYC amplifications specifically in metastatic patients. Collectively, these results implicate MYC activity as a major determinant of metastatic burden in advanced PDAC. SIGNIFICANCE: Here, we investigate metastatic variation seen clinically in patients with PDAC and murine PDAC tumors and identify MYC as a major driver of this heterogeneity. © 2021 The Authors;.
Journal Title: Cancer Discovery
Volume: 12
Issue: 2
ISSN: 2159-8274
Publisher: American Association for Cancer Research  
Date Published: 2022-02-01
Start Page: 542
End Page: 561
Language: English
DOI: 10.1158/2159-8290.Cd-20-1826
PUBMED: 34551968
PROVIDER: scopus
PMCID: PMC8831468
DOI/URL:
Notes: Article -- Export Date: 1 March 2022 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Scott W Lowe
    249 Lowe
  2. Timour Baslan
    46 Baslan
  3. Jonathan J Bermeo
    8 Bermeo